ISIS 113715 is our second-generation antisense inhibitor of protein tyrosine phosphatase 1b, or PTP‑1b, for the treatment of type 2 diabetes. In early trials, ISIS 113715 induced statistically significant improvements...
- Mechanism
- Curator reviewed
ISIS 113715 is our second-generation antisense inhibitor of protein tyrosine phosphatase 1b, or PTP‑1b, for the treatment of type 2 diabetes. PTP‑1b is responsible for turning off the activated insulin receptor, so by reducing levels of PTP‑1b, ISIS 113715 enhances the activity of insulin. Antisense technology allows us to design very specific drugs that inhibit PTP‑1b and that do not inhibit other family members, making it possible to reduce PTP‑1b activity without having other effects on closely related proteins that would likely lead to unwanted side effects.
- Primary indication
- Investigated for use/treatment in diabetes mellitus type 2.Curator reviewed
- Code names
- ISIS 113715
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with ISIS 113715, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account